Did Pantheon Get Enough in Its Buyout?
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
The WHO has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. A few of the Ebola-related stocks are responding.
Ziopharm Oncology saw its shares slide early on Friday after the company announced the pricing of its secondary offering.
G1 Therapeutics expects to offer more than 6 million shares in the range of $15 to $17 apiece in an initial public offering valued up to around $122 million.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and political oversight can still…
Sangamo Therapeutics saw its shares skyrocket early on Thursday after a critical business update.
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
The analysts at Stifel have focused on biotech and specialty pharma companies that not only have data that could prove to be huge, but they are offering aggressive accounts the best entry points in…
With earnings this positive and shares responding as a result, investors have to wonder if Valeant Pharmaceuticals is for real this time, or is this just a head fake.
Canadian pharmaceutical maker Valeant posted a big beat on both earnings and revenues Tuesday morning. The company also raised its adjusted EBITDA guidance for the full fiscal year.
MannKind Corp. (NASDAQ: MNKD) saw its shares make a massive gain on Monday after it was announced that its One Drop Chrome is now available on Amazon Prime. Overall this is huge of the…